Letrozole
NDC Package 24535-0801-1
Package Information
Letrozole is Tablets may cause fetal harm when administered to a pregnant woman and the clinical benefit to premenopausal women with breast cancer has not been demonstrated. Letrozole Tablets is contraindicated in women while taking this drug, the patient should be apprised of the potential hazard to a fetus. Marketed by Arab Pharmaceutical Manufacturing Co. Psc Ltd, this product is identified by NDC 24535-0801 and is authorized under FDA application ANDA203796.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 24535 - Arab Pharmaceutical Manufacturing Co. Psc Ltd
- 24535-0801 - Letrozole
- 24535-0801-1 - 30 TABLET, FILM COATED in 1 BOTTLE
- 24535-0801 - Letrozole
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 24535-0801-1 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Letrozole, labeled by Arab Pharmaceutical Manufacturing Co. Psc Ltd. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Arab Pharmaceutical Manufacturing Co. Psc Ltd on June 03, 2016. The current certification is valid through December 31, 2017.
How is this Arab Pharmaceutical Manufacturing Co. Psc Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 24535080101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.